[Fumaric acid and its esters in the treatment of multiple sclerosis: studies and effects].

Abstract

The currently licensed medications for relapsing-remitting multiple sclerosis (RRMS) are only partially effective and require a parenteral route of administration. Thus there is a need for new, preferably orally available therapeutics. Such a substance could be fumaric acid and its esters (FAE). These compounds are already in use for treatment of psoriasis and are known to have an immunomodulatory effect. In addition there is a potential for neuroprotective effects as suggested by in vitro studies and experiments in the animal model of experimental autoimmune encephalomyelitis. A phase II clinical study in RRMS patients with the modified fumaric acid ester BG-12 showed as "proof of principle" in a frequent MRI design that FAE significantly reduce the number of gadolinium-enhancing lesions after 24 weeks of treatment. Further phase III studies have been started to explore the long-term efficacy of this substance. The results of these studies will show if FAE can be another treatment option, maybe for combination therapy, in patients with MS.

• Authors: M Stangel, D Moharregh-Khiabani, R A Linker, R Gold
• Journal: Der Nervenarzt (Nervenarzt) Vol. 79 Issue 2 Pg. 212-7 (Feb 2008) ISSN: 0028-2804 [Print] Germany
• Vernacular Title: Fumarat in der Behandlung der Multiplen Sklerose : Mögliche Wirkmechanismen und Studien.
• PMID: 18210050 (Publication Type: English Abstract, Journal Article)

Chemical References

• Esters
• Fumarates
• Immunosuppressive Agents
• Neuroprotective Agents
• Dimethyl Fumarate

Topics

• Animals
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Dimethyl Fumarate
• Esters
• Fumarates (adverse effects, therapeutic use)
• Humans
• Immunosuppressive Agents (adverse effects, therapeutic use)
• Mice
• Mice, Inbred C57BL
• Multiple Sclerosis, Relapsing-Remitting (diagnosis, drug therapy)
• Neuroprotective Agents (adverse effects, therapeutic use)
• Treatment Outcome